Co-founder & CEO
Sujeet Singh is Co-founder and Chief Executive Officer of Calyptus Pharmaceuticals. Before co-founding Calyptus, Sujeet was Vice President & Head, Strategic Portfolio & Business Development for Dr. Reddy’s Laboratories (DRL) North America Generics. He was responsible for business strategy, planning, portfolio management, in-licensing, acquisition, integration, and managing external collaborations. During his stint at Dr. Reddy's Sujeet also led the establishment and subsequent launch of the highly successful Specialty Generics (Injectable) business and was involved in setting-up and growing DRL’s Custom Pharma Services business. Sujeet has an MBA from Indian Institute of Management Bangalore, and a B. Tech. from the Indian Institute of Technology, Bombay.
Co-founder & COO
Shubhayu Sinharoy is Co-founder and Chief Operating Officer of Calyptus Pharmaceuticals. Before co-founding Calyptus, Shubhayu was Head of M&A and Business Development for Dr. Reddy’s Laboratories (DRL) North America Generics, where he led external R&D alliances for complex generic assets, in-licensing transactions, acquisitions and strategic growth initiatives. He headed the largest U.S. acquisition for DRL (Product portfolio acquisition from Teva for $350 million), along with acquisition of leading OTC brands from Ducere Pharmaceuticals, and an acquisition of a highly specialized pharma technology company. Prior to DRL, he held roles of increasing responsibility at Eaton, L.E.K. Consulting and Tyco Connectivity. He holds 4 patents. Shubhayu has an MBA from The Wharton School, an M.S. from Michigan Technological University and a B. Tech from the Indian Institute of Technology, Madras.
Co-founder & CSO
Puiho Yuen is Co-founder and Chief Scientific Officer of Calyptus Pharmaceuticals. Before co-founding Calyptus, Pui headed the development of injectable, ophthalmic, topical, softgel and transdermal products for Dr. Reddy’s Laboratories (DRL) North America Generics. He possesses a vast depth of knowledge in generic drug development as well as approval processes and requirements. Prior to DRL, Pui held various pharmaceutical R&D and management roles at Schering-Plough, Baxter and Eagle Pharmaceuticals. Pui led the discovery of mometasone furoate monohydrate and formulation/process development efforts for the commercial success of Nasonex® nasal spray. He holds 11 patents. Pui has a Ph.D. in Pharmaceutics from Ohio State University.